Cost and cost-effectiveness of childhood vaccination against rotavirus in France

被引:56
作者
Melliez, H. [1 ]
Levybruhl, D. [2 ]
Boelle, P. Y. [3 ]
Dervaux, B. [2 ,4 ]
Baron, S. [5 ]
Yazdanpanah, Y. [1 ,2 ,4 ,6 ]
机构
[1] Serv univ Reg Maladies Infect, F-59208 Tourcoing, France
[2] Inst Veille Sanitaire, St Maurice, France
[3] INSERM, U707, Paris, France
[4] URA 362, CNRS, Lab Rech Econ & Sociales, Lille, France
[5] CHRU, Serv Informat Med Epidemiol & Econ Sante, Tours, France
[6] Fac Med Lille, EA 2694, F-59045 Lille, France
关键词
rotavirus; cost-effectiveness; vaccination; morbidity; mortality;
D O I
10.1016/j.vaccine.2007.11.064
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Objectives: To assess the effectiveness and cost-effectiveness of routine childhood vaccination by new vaccines against rotavirus in France. Methods: We constructed a Markov decision tree to compare two alternatives: "no vaccination" and "vaccination". A hypothetical birth cohort of 750,000 children was followed until 3 years of age. First, the disease burden without vaccine was estimated using data from French databases and medical literature. Incidence rates in unvaccinated children were modelled as a function of age and seasons. Next, using data from the medical. literature, the vaccine's protective effect on rotavirus diarrhoea was considered. Results: A routine universal rotavirus immunization programme was estimated capable of annually avoiding 89,000 cases of diarrhoea, 10,500 hospitalizations, and 8 deaths. At a vaccination cost of is an element of 150/course, assuming 75% vaccine coverage, the programme would cost is an element of 95 million and involve a net toss of is an element of 68 million to the health care system. The vaccination programme would cost is an element of 298,000/year of life saved, and is an element of 138,000/QALY saved. Key variables affecting the results were disease incidence, mortality rates and vaccine price. Conclusion: In France, childhood rotavirus vaccination with new antirotavirus vaccines would reduce the morbidity burden of rotavirus infection, but would not be cost-effective unless the price of vaccine decreased considerably. (c) 2007 Elsevier Ltd. All rights reserved.
引用
收藏
页码:706 / 715
页数:10
相关论文
共 48 条
[1]   EVALUATION OF RHESUS ROTAVIRUS MONOVALENT AND TETRAVALENT REASSORTANT VACCINES IN US CHILDREN [J].
BERNSTEIN, DI ;
GLASS, RI ;
RODGERS, G ;
DAVIDSON, BL ;
SACK, DA .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1995, 273 (15) :1191-1196
[2]   EuroQol: The current state of play [J].
Brooks, R .
HEALTH POLICY, 1996, 37 (01) :53-72
[3]   Virus diversity in a winter epidemic of acute diarrhea in France [J].
Chikhi-Brachet, R ;
Bon, F ;
Toubiana, L ;
Pothier, P ;
Nicolas, JC ;
Flahault, A ;
Kohli, E .
JOURNAL OF CLINICAL MICROBIOLOGY, 2002, 40 (11) :4266-4272
[4]   The economic value of childhood varicella vaccination in France and Germany [J].
Coudeville, L ;
Brunot, A ;
Szucs, TD ;
Dervaux, B .
VALUE IN HEALTH, 2005, 8 (03) :209-222
[5]  
DAVIDSON GP, 1975, LANCET, V1, P242
[6]  
*DEVOS, 2004, PEDIATR INFECT DIS J, V23, pS179
[7]   Health care costs of diarrheal disease and estimates of the cost-effectiveness of rotavirus vaccination in Vietnam [J].
Fischer, TK ;
Anh, DD ;
Antil, L ;
Cat, NDL ;
Kilgore, PE ;
Thiem, VD ;
Rheingans, R ;
Tho, LH ;
Glass, RI ;
Bresee, JS .
JOURNAL OF INFECTIOUS DISEASES, 2005, 192 (10) :1720-1726
[8]   The Health Utilities Index (HUI®) system for assessing health-related quality of life in clinical studies [J].
Furlong, WJ ;
Feeny, DH ;
Torrance, GW ;
Barr, RD .
ANNALS OF MEDICINE, 2001, 33 (05) :375-384
[9]   Rotavirus vaccines: current prospects and future challenges [J].
Glass, Roger I. ;
Parashar, Umesh D. ;
Bresee, Joseph S. ;
Turcios, Reina ;
Fischer, Theo K. ;
Widdowson, Marc-Alain ;
Jiang, Baoming ;
Gentsch, Jon R. .
LANCET, 2006, 368 (9532) :323-332
[10]   A PROSPECTIVE-STUDY OF ROTAVIRUS INFECTION IN INFANTS AND YOUNG-CHILDREN [J].
GURWITH, M ;
WENMAN, W ;
HINDE, D ;
FELTHAM, S ;
GREENBERG, H .
JOURNAL OF INFECTIOUS DISEASES, 1981, 144 (03) :218-224